**Appendix 3**

RCTs published since 2000 that have compared bismuth quadruple therapy with other regimens or with a bismuth quadruple regimen of different duration as salvage treatment after one or more failed eradication attempts

1. Bago J, Pevec B, Tomic M, et al. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 2009;121:47-52.
2. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002.
3. Cao Z, Chen Q, Zhang W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol 2015;50:1185-90.
4. Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006;11:46-51.
5. Chuah SK, Tai WC, Hsu PI, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study. Helicobacter 2012;17:374-81.
6. Chung JW, Lee JH, Jung HY, et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011;16:289-94.
7. Georgopoulos SD, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002;16:569-75.
8. Isakov V, Domareva I, Koudryavtseva L, et al. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002;16:1277-82.
9. Jheng GH, Wu IC, Shih HY, et al. Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection. Biomed Res Int 2015;2015:163960.
10. Kang JM, Kim N, Lee DH, et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 2007;12:623-8.
11. Karatapanis S, Skorda L, Georgopoulos S, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection. Annals of Gastroenterology 2009;22:263-267.
12. Kim MS, Kim N, Kim SE, et al. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC Gastroenterol 2013;13:138.
13. Kuo CH, Hsu PI, Kuo FC, et al. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother 2013;68:222-8.
14. Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009;63:1017-24.
15. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45.
16. Magaret N, Burm M, Faigel D, et al. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001;19:174-8.
17. Mantzaris GJ, Petraki C, Petraki K, et al. Prospective, randomized study of seven versus fourteen days omeprazole quadruple therapy for eradication of Helicobacter pylori infection in patients with duodenal ulcer after failure of omeprazole triple therapy. Annals of Gastroenterology 2005;18:330-335.
18. Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003;8:310-9.
19. Moon JY, Kim GH, You HS, et al. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver 2013;7:406-10.
20. Navarro-Jarabo JM, Fernandez N, Sousa FL, et al. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection. BMC Gastroenterol 2007;7:31.
21. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-33.
22. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-24.
23. Perri F, Festa V, Clemente R, et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
24. Perri F, Festa V, Merla A, et al. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2003;18:815-20.
25. Uygun A, Ozel AM, Yildiz O, et al. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol 2008;23:42-5.
26. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:421-7.
27. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:553-60.
28. Wu DC, Hsu PI, Chen A, et al. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest 2006;36:803-9.
29. Wu DC, Hsu PI, Tseng HH, et al. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore) 2011;90:180-5.
30. Yee YK, Cheung TK, Chu KM, et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007;26:1063-7.